Inventor · disambiguated record
Gregory J. Carven
Also filed as: CARVEN GREGORY · CARVEN GREGORY J · CARVEN GREGORY JOHN
18 granted patents·11 pending applications·1,938 citations·filing 2008–2025
94Inventor score
Top patents by PatentIndex Score
29 records- 0197US8952136B2Antibodies to human programmed death receptor PD-1MERCK SHARP & DOHME·Filed 2012·Granted Feb 10, 2015·174 cites·3 claims
- 0297US8900587B2Antibodies to human programmed death receptor PD-1MERCK SHARP & DOHME·Filed 2012·Granted Dec 2, 2014·411 cites·3 claims
- 0397US8354509B2Antibodies to human programmed death receptor PD-1MSD OSS BV·Filed 2008·Granted Jan 15, 2013·1.3k cites·11 claims
- 0494US11439704B2Methods for using anti-myostatin antibodiesSCHOLAR ROCK INC·Filed 2020·Granted Sep 13, 2022·5 cites·12 claims
- 0592US9834605B2Antibodies to human programmed death receptor PD-1MERCK SHARP & DOHME·Filed 2014·Granted Dec 5, 2017·16 cites·9 claims
- 0689US11117961B2Antibodies to human programmed death receptor PD-1MERCK SHARP & DOHME·Filed 2017·Granted Sep 14, 2021·2 cites·57 claims
- 0789US10751413B2Anti-pro/latent-Myostatin antibodies and uses thereofSCHOLAR ROCK INC·Filed 2016·Granted Aug 25, 2020·8 cites·11 claims
- 0887US10875929B2Tissue factor pathway inhibitor antibodies and uses thereofPFIZER·Filed 2019·Granted Dec 29, 2020·3 cites·18 claims
- 0987US2025145732A1Tissue factor pathway inhibitor antibodies and uses thereofPFIZER·Filed 2024·Application pending·0 cites
- 1085US12122823B2Isoform-selective TGFB1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2021·Granted Oct 22, 2024·1 cites·13 claims
- 1185US10550200B2Tissue factor pathway inhibitor antibodies and uses thereofPFIZER·Filed 2016·Granted Feb 4, 2020·5 cites·9 claims
- 1284US11634504B2Tissue factor pathway inhibitor antibodies and uses thereofPFIZER·Filed 2020·Granted Apr 25, 2023·1 cites·8 claims
- 1383US12168698B2Tissue factor pathway inhibitor antibodies and uses thereofPFIZER·Filed 2023·Granted Dec 17, 2024·0 cites·11 claims
- 1478US2021403560A1Antibodies to human programmed death receptor pd-1MERCK SHARP & DOHME·Filed 2021·Application pending·0 cites
- 1578US2024016928A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 1677US11130803B2Isoform-selective TGFβ1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Granted Sep 28, 2021·1 cites·10 claims
- 1777US2025215072A1Isoform-selective tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2024·Application pending·0 cites
- 1873US9428577B2Platelet-derived growth factor B specific antibodies and compositions and uses thereofPFIZER·Filed 2013·Granted Aug 30, 2016·2 cites·7 claims
- 1969US2023348583A1TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOFSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 2067US12281159B2TGFβ antibodies, methods and usesSCHOLAR ROCK INC·Filed 2021·Granted Apr 22, 2025·0 cites·26 claims
- 2164US2019209682A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Application pending·0 cites
- 2263US12252531B2Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitorsSCHOLAR ROCK INC·Filed 2019·Granted Mar 18, 2025·0 cites·5 claims
- 2360US2018207267A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2018·Application pending·0 cites
- 2458US2025257125A1HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOFSCHOLAR ROCK INC·Filed 2025·Application pending·0 cites
- 2547US2019292254A1TGFBeta Antibodies, Methods and UsesSCHOLAR ROCK INC·Filed 2017·Application pending·0 cites
- 2646US11643459B2TGFβ1-binding immunoglobulins and use thereofSCHOLAR ROCK INC·Filed 2017·Granted May 9, 2023·0 cites·15 claims
- 2745US2021340238A1TGFß1 INHIBITORS AND USE THEREOFSCHOLAR ROCK INC·Filed 2019·Application pending·0 cites
- 2844US12358992B2LTBP complex-specific inhibitors of TGF-beta 1 and uses thereofSCHOLAR ROCK INC·Filed 2018·Granted Jul 15, 2025·0 cites·4 claims
- 2944US2020181251A1Lrrc33 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →